Gengnianshou formula inhibits estrogen deficiency induced obesity via an HSPA5-associated phosphatidylcholine (PC) regulatory pathway: Ethnopharmacological relevance and mechanistic insights from network pharmacology and
Zhang W., Zhang WT., Fan JX., Wang YY., Kang MJ., Li X.
Randomized Controlled Trial with a reported sample of 6, published in J Ethnopharmacol (2026) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Randomized Controlled Trial
- Journal
- J Ethnopharmacol (2026)
- Country
- Ireland
- Reported sample size
- 6
- Source database
- PubMed
- PMID
- 42178075
- DOI
- 10.1016/j.jep.2026.121886
Abstract (original English)
Ethnopharmacological relevance Gengnianshou Formula (GNS), a traditional Chinese medicine formula composed of 9 herbs, has long been used for regulating menopausal syndromes based on the TCM theory. However, its mechanistic basis for ameliorating perimenopausal obesity (a common estrogen deficiency-induced metabolic disorder) remains unelucidated. Aim of the study This study aimed to investigate the anti-obesity effects of GNS under estrogen-deficient conditions and to explore the potential involvement of HSPA5 and phosphatidylcholine (PC) metabolism using network pharmacology and multi-omics approaches. Materials and methods An ovariectomized (OVX) rat model was established using female Sprague-Dawley rats, which were randomly assigned to six groups (n = 6 per group) to evaluate the therapeutic effects of GNS. Network pharmacology analysis was conducted to identify potential targets. Transcriptomics and lipidomics analyses were integrated to explore molecular alterations. In vitro experiments using human adipose-derived stem cells (hADSCs) under estrogen-deprived conditions were performed to functionally validate the role of HSPA5 through siRNA-mediated knockdown, followed by Oil Red O staining and gene expression analysis. Results The OVX model successfully induced obesity, as evidenced by significant increases in body weight, visceral and subcutaneous white adipose tissue (v
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.